# A catalogue of molecular targets for kidney function from genetic analyses of a million individuals

# **Supplementary Materials**


Matthias Wuttke, Yong Li, Man Li, Karsten B. Sieber, Mary F. Feitosa, Mathias Gorski et al.

Supplementary Figure 1: Analysis Flowchart	2
Supplementary Figure 2: Regional Association Plots	3
Supplementary Figure 3: Genetic Heritability	4
Supplementary Figure 4: BUN Manhattan plot	5
Supplementary Figure 5: Genetic Risk Score	6
Supplementary Figure 6: Genetic correlation plot	7
Supplementary Figure 7: Pathway and tissue enrichment analysis with DEPICT	8
Supplementary Figure 8: Co-localization of eGFR-association signals with gene expression across 44 GT tissues and two kidney tissues	
Extended acknowledgements and study funding information	13

Supplementary Tables are provided separately as a spreadsheet.

## **Supplementary Figure 1: Analysis Flowchart**

**Panel A.** Flowchart of trans-ethnic GWAS meta-analysis (GWAMA) and follow-up to discover and characterize genetic associations with kidney function. **Panel B.** Fine-mapping and co-localization analyses to highlight effector genes and causal variants among participants of EA.



## **Supplementary Figure 2: Regional Association Plots**


Regional Association Plot Booklet for all 308 loci identified in association with eGFR through trans-ethnic meta-analyses.

PDF-booklet available online:

https://www.dropbox.com/s/snf5xyqqpi0sbll/RAPs\_ALL\_4\_per\_page.pdf?dl=0


### **Supplementary Figure 3: Genetic Heritability**

Distribution of the genetic heritability ( $h^2$ ) estimates of age- and sex-adjusted log(eGFR) residuals in the Cooperative Health Research In South Tyrol (CHRIS) study, for index SNPs from the trans-ethnic (**Panel A**) and EA-specific (**Panel B**) GWAS.  $h^2$  distribution is shown before (gray) and after (green) inclusion of the index SNPs into the model, with the shift representing the amount of  $h^2$  explained by the index SNPs.




# Supplementary Figure 4: BUN Manhattan plot

Manhattan plot of results from the GWAS meta-analysis of blood urea nitrogen (BUN).



## Supplementary Figure 5: Genetic Risk Score


Association between a genetic risk score (GRS) for low eGFR and clinical phenotypes abstracted from ICD-10 codes independent individuals from the UK Biobank. Asthma and Schizophrenia were included as a negative control. Displayed are odds ratios and their 95% CIs per standard deviation increase in GRS (Methods).



Odds Ratio per GRS SD increase

## **Supplementary Figure 6: Genetic correlation plot**


Genetic correlation plot based on the summary statistics from the trans-ethnic GWAS metaanalysis of eGFR and 748 other complex traits and diseases available through LD Hub.



The genetic correlations with citrate and cystatin C were not significant ( $P=6.0\times10^{-4}$  and  $4.0\times10^{-4}$ , respectively, **Supplementary Table 8**), because these traits were measured in a limited number of studies, resulting in smaller GWAS sample sizes.

#### Supplementary Figure 7: Pathway and tissue enrichment analysis with DEPICT


Shown is the barplot of the results of the tissue and cell type enrichment analysis in **Panel A**. Cells, tissues and physiological systems are highlighted in blue, if the association FDR was smaller than 0.05 and are summarized in the table in **Panel B**. **Panel C** illustrate the highly correlated and strongly associated meta gene sets ( $P < 1.x10^{-6}$ , FDR <0.05) from the pathway and gene-set enrichment analysis clustered according to their biological relevance for kidney function, energy metabolism and signaling and transcription.



# В


Enriched tissues and cell types identified by DEPICT. Shown are the tissues and cell types significantly (FDR<0.05) enriched in the meta-analysis results of subjects from all ethnicities.

MeSH term	Name	MeSH 1 <sup>st</sup> level term	MeSH 2 <sup>nd</sup> level term	Nominal P-value
A05.810	Urinary Tract	Urogenital System	Urinary Tract	4.99x10 <sup>-7</sup> *
A05.810.453	Kidney	Urogenital System	Urinary Tract	7.84x10 <sup>-7</sup> *
A03.620	Liver	Digestive System	Liver	6.46x10 <sup>-5</sup> *
A11.436.348	Hepatocytes	Cells	Epithelial Cells	1.38x10 <sup>-4</sup> *
A10.615	Membranes	Tissues	Membranes	3.14x10 <sup>.4</sup> *
A10.615.550	Mucous Membrane	Tissues	Membranes	6.30x10 <sup>-4</sup> *
A10.615.550.760	Respiratory Mucosa	Tissues	Membranes	1.15x10 <sup>-3</sup>
A04.531.520	Nasal Mucosa	Respiratory System	Nose	1.15x10 <sup>-3</sup>
A09.531	Nose	Sense Organs	Nose	1.15x10 <sup>-3</sup>
A11.436	Epithelial Cells	Cells	Epithelial Cells	1.28x10 <sup>-3</sup>
A10.690	Muscles	Tissues	Muscles	1.72x10 <sup>-3</sup>
A10.272	Epithelium	Tissues	Epithelium	2.42x10 <sup>-3</sup>
A10.690.552	Muscle Striated	Tissues	Muscles	3.78x10 <sup>-3</sup>
A10.690.552.500 A03.556.249.249.	Muscle Skeletal	Tissues	Muscles	3.78x10⁻³
356.668	Colon Sigmoid	Digestive System	Gastrointestinal Tract	3.90x10 <sup>-3</sup>
A05 810 453 324	Kidney Cortex	Urogenital System	Urinany Tract	4 64-10-3




# Supplementary Figure 8: Co-localization of eGFR-association signals with gene expression across 44 GTEx tissues and two kidney tissues

All eGFR loci were tested for co-localization with all eQTLs where the eQTL cis-window overlapped ( $\pm 100$  kb) the sentinel genetic variants. Genes with at least one positive co-localization (posterior probability of one common causal variant, H4,  $\ge 0.80$ ) in any of the 44 tissues for which eQTL data was released by the GTEx Project or in two renal tissue are illustrated with the respective sentinel variants (Y-axis). Co-localizations across all tissues (X-axis) are illustrated as dots, where the size of the dots indicates the posterior probability of the co-localization. Negative co-localizations (posterior probability of H4 <0.80) are grey, while the positive co-localizations are color-coded based on the predicted change in expression relative to the allele associated with lower eGFR.




#### Supplementary Figure 8 – continued (2/4)



## **Supplementary Figure 8** – continued (3/4)

ATF1, rs7966357	
CERS5, rs7966357 DIP28, rs7966357	
LIMA1, rs7966357 -	
METTL7A, rs7966357 - 💭 • 🗘 • • • • • • • • • • • • • • • • •	
CELF1, rs10838702 - PSMC3, rs10838702 -	
PLD6, rs1242484	
RAI1, rs1242484 -	
RASD1, rs1242484	
EN8P1/ rs7543734	
SNOR466, rs7543734	• • • • • • • • • • • • • • • • • • • •
MARC1, rs7514450 RNU64TAC36P, rs7514450	
RNU6ATAC36P, rs7514450	
CASP9, rs11260709	
DNAJC16, rs11260709	00.00.000
AHR, rs4410790	
PSMD0-AS2, rs66473811 - MTMR3, rs2074204 -	
	·····
SRRM2-AS1, rs1635404 TCEB2, rs1635404	
TRAP1, rs1635404 🛑 🔸 COOCCOD@CCCOD@CCCO@CCCCO	100+000000000000000000
TMEM60B, rs2834317	
NDOR1, rs10122824 QSOX2, rs10122824	
SNAPC4, rs10122824	• • • • • • • • • • • • • • • • • • • •
ARG1, rs9375818	· • • • • • • <u>.</u> · • • • • • • • • • • • • • • • • • •
ENPP1, rs9375818 AP1G1, rs52053077	
MARVELD3, rs62053077 📕 • • 🗘 🛛 😡 🖓	] _ @+ _ + + + + + + + + + + + + + +
PHLPP2, rs62053077 -	<u>]</u> /*··· <b>*</b> * <b>@</b> ***/*··***
KNG1, rs11919484	
APEH, rs4625	
LSMEM2, rs4625	
MST1, rs4625	
PRKAR2A-AS1, rs4625	
SLC26A6, rs4625	
TMA7, rs4625	
TREX1, rs4625-000000000000000000000000000000000000	)00000+0++++00000+00 + (0.2, 0.4)
F4M06EP; rs363092 -	p (0.4.0.6)
	· · · · · · · · · · · · · · · · · · ·
MOAP1, r\$35629566	
RIN3, rs35629566 CCL19, rs544169	
NT6C34, rs6948759	
PFKFB2, is78986840-	011121110110211101111
VOD1, rs78986840	
PCMTD2, rs2261092 - 0 + 0 + + + + + + + + + + + + + + + +	
TNFRSF6B, rs2261092	
TNFRSF68, rs2261092	Change in gene expression
TNFRSF6B, rs2261092	Change in gene expression
TNFRS/F86, rs225/1092- ETNIPPL, rs7687209- RPL34, rs7687209- AGFG1, rs13029395- AGFG4, rs13029395-	Change in gene expression with decreased eGFR
TNFRS/B8, rs225/1092- ETNPPL, rs7687209- RPL34, rs7687209- AGFG1, rs13029395- ABCG4, rs2509851- C2C02L, rs2509851-	Change in gene expression with decreased eGFR
TNFRS/F86, rs225/1092- ETNIPPL, rs7687209- AGFG7, rs13029395- AGFG7, rs13029395- C2CO2L, rs2503951- C2CO2L, rs2503051- C2CO2L,	Change in gene expression with decreased eGFR
TNFRS/R8[, n225/1092 ETNPEL, n37587209 RPL34, n37587209 AGFG1, n313023395 ABCG4, n2509851 C2C02163, n2509851 HINFP, n2509851 C2C02163, n2509851 HINFP, n2509851 C2C02163, n2509851 C2C02164, n250985	Change in gene expression with decreased eGFR
TNFRS/F86, rs225/1092- ETN/F9L, rs7687209- RPL34, rs7687209- AGFG1, rs13029395- C2CO2L, rs2509851- C2CO2L, rs2509851- CCDC 163, rs2509851- CCDC 163, rs2509851- CCLF1, rs7127946- PSMC5, rs7127946-	Change in gene expression with decreased eGFR
TNFRS/F86, rs225/1092- ETMPEL, rs7587209- AGFG1, rs13029395- AGFG4, rs13029395- C2C02L, rs250985- C2C02L, rs250985- C2C02L, rs250985- C2LP7, rs7127945- CA11, rs281380- IZUMO1,	Change in gene expression with decreased eGFR
TNFRS/R8[, n225/1092- ETNPEL, n7587209- RPL34, n7587209- AGC61, n13023935- ABC64, n2509851- C2CD21, n2509851- C2CD2153, n2509851- HINPF, n2509851- CELF1, n21/27946- PSMC3, n21/27946- CA11, n281380- IZUMO1, n281380-	Change in gene expression with decreased eGFR
TNFRS/R8(n:2261092 ETNPEL, n:75877209 AGFG1, n:13023955 ABCG4, n:2509651 C2C02L, n:2509651 C2C02L, n:2509651 C2C02L, n:2509651 CELF1, n:7127946 CELF1, n:7127946 CA11, n:281380 IZUMO1, n:281380 MAMSTR, n:281380 MAMSTR, n:281380	Change in gene expression with decreased eGFR
TNFRS/F86, rs225/1092- ETN/F8/, rs257/209- RPL34, rs7587/209- AGFG1, rs13029395- C2CO2L, rs2509851- C2CO2L, rs2509851- CELF1, rs2509851- CELF1, rs7127946- CA11, rs281380- IZUMO1, rs231380- MAMSTR, rs281380- NTN6, rs2	Change in gene expression with decreased eGFR
TNFRS/F86, rs2261092 ETNIPEL rs7887209 AGFG1, rs130239851 C2C02L, rs130239851 C2C02L, rs130239851 C2C02L, rs130239851 C2C02L, rs127346 C6LF1, rs127346 C6LF1, rs127346 CA11, rs281380 IZUMO1, rs281380 NTN6, rs2813	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.02 0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.03 -0.03 -0.03 -0.03 -0.01 -0.03 -0.03 -0.01 -0.03 -0.01 -0.03 -0.01 -0.03 -0.01 -0.03 -0.01 -0.01 -0.03 -0.01 -0.01 -0.03 -0.01 -0.01 -0.03 -0.01 -0.01 -0.03 -0.01 -0.01 -0.03 -0.01 -0.03 -0.01 -0.01 -0.03 -0.01 -0.01 -0.03 -0.01 -0.03 -0.01 -0.03 -0.01 -0.03 -0.01 -0.03 -0.01 -0.03 -0.01 -0.03 -0.01 -0.03 -0.01 -0.03 -0.01 -0.03 -0.03 -0.01 -0.03 -0.03 -0.01 -0.03 -0.01 -0.03 -0.03 -0.01 -0.03 -0.01 -0.03 -0.03 -0.01 -0.03 -0.03 -0.01 -0.03 -0.03 -0.03 -0.01 -0.03 -0.03 -0.01 -0.03 -0.03 -0.03 -0.03 -0.03 -0.01 -0.03 -0.03 -0.03 -0.03 -0.03 -0.01 -0.02 -0.03
TNFRS/R86, nr226/1092 ETNPEL, nr3587209 AGFG1, nr13023955 ABCG4, nr2509851 C2C02163, nr2509851 C2C02163, nr2509851 HINPE, nr2509851 CELF1, nr1127946 PSMC3, nr127946 CA11, nr281380 IZUMO1, nr281380 RASIPI, nr281380 RASIPI, nr281380 CA11, nr28	Change in gene expression with decreased eGFR
TNFRS/R8(, n226/1092 ETNIPEL, n37897209 AGFG1, n313023955 ABCG4, n2203651 C2C02L, n2503651 CEDC/153, n2503651 CELF1, n37127946 CA11, n281380 AMA/STR, n281380 NTN6, n281380 RASIP1, n281380 CA15, n25072105 CC0C0C, n35072105 CC0C0C, n35072105 CC0C0C0C, n35072105 CC0C0C0C0C0C0C0C0C0C0C0C0C0C0C0C0C0C0C	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03
TNFRS/R86, rs2261092 ETN/R8/R87/209 AGFG1, rs13023995 ABCG4, rs2509651 C2C021, rs250961 C2C021, rs250961 C2C0	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03
TNFRS/R85, rs2261092 ETNPL, rs7587209 AGFG1, rs13023955 ABCG4, rs2509851 C2CDC163, rs2509851 C2CDC163, rs2509851 CELF1, rs7127946 PSMC3, rs7127946 CA11, rs281380 IZUMO1, rs281380 ASUP1, rs251380 CA11, rs281380 CA11, rs2804300 CA11, rs28	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03
TNFRS/R86, rs2261092 ETN/R8/R87/209 AGFG1, rs13023995 ABCG4, rs2509651 C2C021, rs250961 C2C021, rs250961 C2C0	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03
TNFRS/R8(m:2261092 ETINPL, m3787209 AGFG1, m3023985 ABCG4, m2509851 C2C021, m2509851 C2C021, m2509851 C2C021, m2509851 HINFP, m2509851 C2LF1, m3127946 CA11, m281380 IZUMO1, m281380 RASIP1, m281380 RASIP1, m281380 TNTKS m281380 RASIP1, m281380 C4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 -0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03
TNFRS/R86, m226/1092      ETNPEL, m7587209      ABC94, m7587209      ABC94, m2509851      C2C021, m2509851      C2C021, m2509851      C2C021, m2509851      C2C021, m2509851      C2C021, m2509851      C2C021, m2509851      C2LF1, m7127946      PSMC3, m7127946      CA11, m281380      MARSTR, m281380      MARSTR, m281380      MARSTR, m281380      MARSTR, m281380      MUC0174, m281380      GUSB, m35072105      VKORC111, m35072105      VKORC111, m35072105      MDOR11, m28404300      USP36, m11237450      SNAPC4, m28404300      USP35, m11237450	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.02 0.01 -0.01 -0.02 -0.03
TNFRS/R08, m226/1092      ETINPL, m2587209      AGFG1, m13027209      AGFG1, m13023955      C2C02163, m2509851      CCDC/163, m2509851      CELF1, m2127946      PSMC3, m2127946      CA11, m231380      IZUMOV, m281380      MASTR, m25072105      MAMASTR, m25072105      MAMASTR, m25072105      MAMASTR, m25072105      NTNK m281380      RASUP, m2503801      CUTO7, m3072105      TPST1, m3072105      VKORCL1, m3072105      SMAPC4, m28404308      CUMVD14, m28404308      CUMMPC4, m28404308      CUMMPC4, m28404308      CUMMPC6, m28404308	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.02 0.01 -0.01 -0.02 -0.03
TNFRS/R08, m2261092      ETINPL, m2587209      AGFG1, m13023955      ABCG4, m2509851      C2C021, m2509851      C2C021, m2509851      CELF1, m3127946      PSMC3, m2127946      PSMC3, m2127946      C411, m231380      RASTF, m251380      RASTF, m251380      RASTF, m251380      RASIP1, m281380      RASIP1, m281380      RASIP1, m281380      RASIP1, m281380      RASIP1, m281380      RCT07, m3072105      NDORT, m39072105      NDORT, m39072105      NDORT, m28404308      SMAPC4, m28404308      USP36, m11274450      IRF6, m52491533      AGP0, m1994887	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.03 0.02 0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.03 -0.03 -0.03 -0.03 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.03 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.03 -0.03 -0.03 -0.01 -0.02 -0.03 -0.0
TNFRSFR8[, nr2261092 ETNPFL, nr2867209 AGFG1, tra13023985 ABCG4, nr2509851 C2C02L, nr2509851 HINFF, nr2809851 C2C02L, nr2509851 HINFF, nr281380 AAMSTR, nr281380 AAMSTR, nr281380 AAMSTR, nr281380 AAMSTR, nr281380 AAMSTR, nr281380 AAMSTR, nr281380 AAMSTR, nr281380 AMAMSTR, nr28149487 AMAMSTR, nr284887 AMAMSTR, nr2844887 AMAMSTR, nr2844887 AMA	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03
TNFRS/R08, m2261092      ETINPL, m2587209      AGFG1, m13023955      ABCG4, m2509851      C2C021, m2509851      C2C021, m2509851      CELF1, m3127946      PSMC3, m2127946      PSMC3, m2127946      C411, m231380      RASTF, m251380      RASTF, m251380      RASTF, m251380      RASIP1, m281380      RASIP1, m281380      RASIP1, m281380      RASIP1, m281380      RASIP1, m281380      RCT07, m3072105      NDORT, m39072105      NDORT, m39072105      NDORT, m28404308      SMAPC4, m28404308      USP36, m11274450      IRF6, m52491533      AGP0, m1994887	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.03 0.02 0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.03 -0.03 -0.03 -0.03 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.03 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.03 -0.03 -0.03 -0.01 -0.02 -0.03 -0.0
TNFRS/R86, nr226/1092 ETNPEL, nr2567/209 AGCFd, nr31023995 ABCC4, nr2509851 C2CDC153, nr2509851 C2CDC153, nr2509851 C2LP1, nr21/27946 PSMC3, nr2127946 CA11, nr281380 IZUMO1, nr281380 AGSP, nr3927105 TPST1, n35072105 TPST1, n35072105 CDC000 CDC000 CDC000 CDC000 CDC000 CDC000 CDC000 CDC000 CDC000 CDC00 CDC00 CDC000 CDC	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03
TNFRS/R8[, n226/1092 ETNPL, n7587209 AGFG1, n31023985 ABCG4, n2509851 C2C021, n2509851 C2C021, n2509851 C2C021, n2509851 C2LF1, n21/27946 CA11, n231380 NAMSTR, n281380 NAMSTR, n281380 NAMSTR, n281380 NAMSTR, n281380 NTNK6, n2251380 CEUCOT/4, n32972105 NCT07, n35072105 NCT07, n35072105 NCT07, n35072105 NCT07, n35072105 NCT07, n35072105 NCT07, n35072105 NCT07, n35072105 NCT07, n35072105 NDCR1, n28404308 QSOK2, n28404308 QSOK2, n28404308 QSOK2, n28404308 CUH295, n11237460 US260 SNAPC4, n28404308 CUH295, n11237460 US260 CCDT27, n35972105 NDCR1, n28404308 QSOK2, n28404308 CUH295, n11237460 US260 NDCR1, n28404308 CUH295, n11237460 US260 NDCR1, n28404308 CDH1292, n76231503 ACP9, n35971221 CDH1292, n76231503 ACP9, n35971221 CDH1292, n76231503 ACP9, n35971221 CDH1292, n3791221 CDH1292, n3791221 CDH1202 CDH1292, n3791221 CDH1292, n379	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03
TNFRS/R05, m2261092      ETNPFL, m2587209      AGFG1, m13023955      ABCG4, m2509851      C2C0212, m2509851      C2C0212, m2509851      C2LF1, m2127946      PSMC3, m2127946      C411, m231380      MARSTR, m251380      MARSTR, m251380      MARSTR, m251380      RASUP1, m251380      MARSTR, m251380      RASUP1, m2540300      UNCORT, m35072105      NDORT, m35072105      NDORT, m28404308      QSOK2, m28404308      QSOK2, m28404308      QSOK2, m28404308      MVZAP, m1594887      GOUM1, m1594887      MNRNP3P11, m1594887      MVZAP, m1594887      GOUM1, m39191221      SNAP1, m3791221	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03
TNFRS/R86, nr226/1092 ETNPEL, nr256/71, nr250/20951 ABC/64, nr250/20951 C2C/02L, nr250/20951 C2C/02L, nr250/20951 C2C/02L, nr250/20951 C2C/02L, nr250/20951 C2C/02L, nr250/20951 C2C/02L, nr250/20951 C2L/17, nr21/2746 PSMC3, nr21/2746 CA11, nr281/380 AUSTR, nr281/380 AUSTR, nr281/380 GUSB, nr350/72105 TPST1, nr350/72105 TPST1, nr350/72105 ADC/R, nr2840/300 SNAPC4, nr2840/300 C2C/02L, nr280/300 C2C/02L/11, nr350/72105 TPST1, nr350/72105 C2C/02L/11, nr350/72105 C2C/02L/11, nr350/72105 C2C/02L/11, nr350/72105 C2C/02L/11, nr350/72105 AUC/R, nr2840/300 C2C/02L/11, nr350/72105 ADC/R, nr2840/300 C2C/02L/11, nr350/72105 ADC/R, nr2840/300 C2C/02L/11, nr350/72105 C2C/02L/11, nr350/72105 C2C/	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00
TNFRS/R86, nr226/1092 ETNPEL, nr256/71, nr250/20951 ABC/64, nr250/20951 C2C/02L, nr250/20951 C2C/02L, nr250/20951 C2C/02L, nr250/20951 C2C/02L, nr250/20951 C2C/02L, nr250/20951 C2C/02L, nr250/20951 C2L/17, nr21/2746 PSMC3, nr21/2746 CA11, nr281/380 AUSTR, nr281/380 AUSTR, nr281/380 GUSB, nr350/72105 TPST1, nr350/72105 TPST1, nr350/72105 ADC/R, nr2840/300 SNAPC4, nr2840/300 C2C/02L, nr280/300 C2C/02L/11, nr350/72105 TPST1, nr350/72105 C2C/02L/11, nr350/72105 C2C/02L/11, nr350/72105 C2C/02L/11, nr350/72105 C2C/02L/11, nr350/72105 AUC/R, nr2840/300 C2C/02L/11, nr350/72105 ADC/R, nr2840/300 C2C/02L/11, nr350/72105 ADC/R, nr2840/300 C2C/02L/11, nr350/72105 C2C/02L/11, nr350/72105 C2C/	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.02 -0.03 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.03 -0.02 -0.03 -0.03 -0.03 -0.02 -0.03 -0.03 -0.03 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.03 -0.03 -0.03 -0.03 -0.03 -0.03 -0.03 -0.02 -0.03 -
TNFRS/R06, m226/1092      FFI-34, m7587209      AGFG1, m13023955      ABCG4, m2509851      C2C021, m2509851      C2C021, m2509851      C2FF1, m3127946      PSMC3, m3127946      C411, m231380      MARSTR, m281380      MARSTR, m281380      RASIP1, m28140308      CUMORTA, m3972105      TNPST, m35072105      NDORT, m28404308      SMAPC4, m28404308      CDH12P2, m194887      GCOM1, m1948887      GCOM1	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.04 -0.02 -0.03 -0.04 -0.05 -0
TNFRS-R86, nr2261092 ETNPEL, nr3587209 ABCG4, nr2509851 CCDC153, nr2509851 CCDC153, nr2509851 CCDC153, nr2509851 CCLF1, nr2127946 PSMC3, nr2127946 CA11, nr2291380 MARSTE, nr281380 MARSTE, nr281380 GUSB, nr31072105 LINC00174, nr28140308 GUSB, nr31072105 LINC00174, nr28140308 GUSB, nr31072105 LINC00174, nr28140308 GUSB, nr31072105 LINC00174, nr28140308 GUSB, nr31072105 LINC00174, nr28140308 GUSB, nr31072105 LINC00174, nr284487 GCCM1, nr391221 GUSB, nr3191221 GUSB, nr3191221 GUSTA, rr6458868 GISTA7, rr6458868 GISTA7, rr6458868 ALMS1F, nr2841902 MAR, nr7241902 MARSTE, nr2841902 MARSTE, nr2841902 MARSTE, nr2841902 MARSTE, nr3104122 GISTA7, rr6458868 GISTA7, rr6458868 ALMS1F, nr72841902 MARSTE, nr2841902 MARSTE, nr2841902 MARSTE, nr3104122 GISTA7, rr6458868 GISTA7, rr6458868 GISTA7, rr6458868 GISTA7, rr6458868 ALMS1F, nr72841902 MARSTE, nr3104192 MARSTE, nr31041	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03
TNFRS/R86, m226/1092 ETNPL, m7587209 AGC61, m13029851 C2C021, m2509851 C2C021, m2509851 C2C021, m2509851 C2C0213, m2509851 C2C0213, m2509851 C2C0213, m2509851 C2C0213, m2509851 C2C0213, m2509851 C2C0213, m2509851 C2C0213, m2509851 C2C0214, m25092105 C2C0214, m25072105 C2C0214, m25072105 C2C0214 C2C0214, m25072105 C2C0214	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03
TNFRS/R06, m226/1092      FFI-34, m7587209      ABCr64, m2509851      C2CD21, m2509200      C2CD21, m2509200      C2CD21, m2509200      C2CD200, m2840300      C2CD200, m2840300      C2CD200, m2840300 <td>Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03</td>	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03
TNFRS/R06, m226/1092      AGFG1, m130203955      AGC64, m2509851      C2C02163, m2509851      HNNFP, m2509851      C2C02163, m2509851      C2LC113, m2509851      C2LC113, m2509851      C2LC113, m2509851      C2LC113, m2509851      C2LC113, m2509851      C2LC113, m2509851      C2LT1, m2127946      PSMC3, m2127946      C311, m231380      MAMSTFR, m281380      RASUP1, m281380      RASUP1, m281380      RCT07, m35072105      WKORC11, m35072105      TPST1, m35072105      NDOR1, m2840308      C2LMM00174, m35072105      NDOR1, m28404308      C0000, m000      SNAPC4, m28404308      C0017, m39072105      NDOR1, m28404308      C0000, m000      SNAPC4, m28404308      C0017, m39072105      REF, m52491533      MCOR1, m3991221      SNAPC4, m28404308      C0112P2, m76215063      ACP4, m394887      GCOM1, m1994887      GCOM1, m1994887      GCOM1, m1994887      GCOM1, m1994887 <td>Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.04 -0.02 -0.03 -0.03 -0.04 -0.02 -0.03 -0.04 -0.02 -0.03 -0.04 -0.04 -0.05 -0.04 -0.05 -0.0</td>	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.04 -0.02 -0.03 -0.03 -0.04 -0.02 -0.03 -0.04 -0.02 -0.03 -0.04 -0.04 -0.05 -0.04 -0.05 -0.0
TNFRS/R08, m22610922      FFIJ4, m7587209      ABC64, m2509851      C20021, m2509851      C20021, m2509851      C20021, m2509851      C2007153, m2509851      C2007163, m2509851      C2007163, m2509851      C2017, m2102946      PSMC3, m7127946      PSMC4, m213980      C411, m231380      IZUMO1, m281380      GUSB, m35072105      TPST1, m35072105      TPST1, m35072105      MDOR1, m28404308      JUSP36, m11237450      JIF6, m23491533      GUSB, m35072105      TPST1, m35072105      MDOR1, m28404308      JUSP36, m11237450      JIF6, m5491533      GCDH12P2, m194887      HNRNP, m391221      SNAPC4, m28404308      GCDM1, m194887      HNRNPART1, m194887      HNRNPART1, m194887      HNRNPART1, m194887      HNRNPART1, m194887      GCDM1, m194887   <	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03
TNFRS/R06, m226/1092      AGFG1, m130203955      AGC64, m2509851      C2C02163, m2509851      HNNFP, m2509851      C2C02163, m2509851      C2LC113, m2509851      C2LC113, m2509851      C2LC113, m2509851      C2LC113, m2509851      C2LC113, m2509851      C2LC113, m2509851      C2LT1, m2127946      PSMC3, m2127946      C311, m231380      MAMSTFR, m281380      RASUP1, m281380      RASUP1, m281380      RCT07, m35072105      WKORC11, m35072105      TPST1, m35072105      NDOR1, m2840308      C2LMM00174, m35072105      NDOR1, m28404308      C0000, m000      SNAPC4, m28404308      C0017, m39072105      NDOR1, m28404308      C0000, m000      SNAPC4, m28404308      C0017, m39072105      REF, m52491533      MCOR1, m3991221      SNAPC4, m28404308      C0112P2, m76215063      ACP4, m394887      GCOM1, m1994887      GCOM1, m1994887      GCOM1, m1994887      GCOM1, m1994887 <td>Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.04 -0.02 -0.03 -0.04 -0.04 -0.05 -0.04 -0.05 -0.0</td>	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.04 -0.02 -0.03 -0.04 -0.04 -0.05 -0.04 -0.05 -0.0
TNFRS/R06, m226/1092      AGFG1, m13023395      AGC64, m2509851      C2C02163, m2509851      HNNFP, m2509851      C2C02163, m2509851      C2LD2163, m2509851      C2LM017, m251380      MAMSTFR, m251380      RASUPT, m251380      RASUPT, m251380      RASUPT, m251380      RCTD7, m35072105      VKORC111, m35072105      MDOR1, m28404308      CULUR00174, m35072105      TNP517, m35072105      MDOR1, m28404308      CULUR028, m31533      COMOR1, m28404308      COMOR1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GSTA1, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m64588866      GSTA2,	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.04 -0.02 -0.03 -0.04 -0.04 -0.05 -0.04 -0.05 -0.0
TNFRS/R06, m226/1092      AGFG1, m13023395      AGC64, m2509851      C2C02163, m2509851      HNNFP, m2509851      C2C02163, m2509851      C2LD2163, m2509851      C2LM017, m251380      MAMSTFR, m251380      RASUPT, m251380      RASUPT, m251380      RASUPT, m251380      RCTD7, m35072105      VKORC111, m35072105      MDOR1, m28404308      CULUR00174, m35072105      TNP517, m35072105      MDOR1, m28404308      CULUR028, m31533      COMOR1, m28404308      COMOR1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GSTA1, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m64588866      GSTA2,	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.04 -0.02 -0.03 -0.04 -0.04 -0.05 -0.04 -0.05 -0.0
TNFRS/R06, m226/1092      AGFG1, m13023395      AGC64, m2509851      C2C02163, m2509851      HNNFP, m2509851      C2C02163, m2509851      C2LD2163, m2509851      C2LM017, m251380      MAMSTFR, m251380      RASUPT, m251380      RASUPT, m251380      RASUPT, m251380      RCTD7, m35072105      VKORC111, m35072105      MDOR1, m28404308      CULUR00174, m35072105      TNP517, m35072105      MDOR1, m28404308      CULUR028, m31533      COMOR1, m28404308      COMOR1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GSTA1, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m64588866      GSTA2,	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.04 -0.02 -0.03 -0.04 -0.04 -0.05 -0.04 -0.05 -0.0
TNFRS/R06, m226/1092      AGFG1, m13023395      AGC64, m2509851      C2C02163, m2509851      HNNFP, m2509851      C2C02163, m2509851      C2LD2163, m2509851      C2LM017, m251380      MAMSTFR, m251380      RASUPT, m251380      RASUPT, m251380      RASUPT, m251380      RCTD7, m35072105      VKORC111, m35072105      MDOR1, m28404308      CULUR00174, m35072105      TNP517, m35072105      MDOR1, m28404308      CULUR028, m31533      COMOR1, m28404308      COMOR1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GSTA1, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m64588866      GSTA2,	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.04 -0.02 -0.03 -0.04 -0.04 -0.05 -0.04 -0.05 -0.0
TNFRS/R06, m226/1092      AGFG1, m13023395      AGC64, m2509851      C2C02163, m2509851      HNNFP, m2509851      C2C02163, m2509851      C2LD2163, m2509851      C2LM017, m251380      MAMSTFR, m251380      RASUPT, m251380      RASUPT, m251380      RASUPT, m251380      RCTD7, m35072105      VKORC111, m35072105      MDOR1, m28404308      CULUR00174, m35072105      TNP517, m35072105      MDOR1, m28404308      CULUR028, m31533      COMOR1, m28404308      COMOR1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GCOM1, m1594887      GSTA1, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m6458866      GSTA2, m64588866      GSTA2,	Change in gene expression with decreased eGFR 0.03 0.02 0.01 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 0.00 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.01 -0.02 -0.03 -0.03 -0.02 -0.03 -0.03 -0.04 -0.02 -0.03 -0.04 -0.04 -0.05 -0.04 -0.05 -0.0

#### Supplementary Figure 8 – continued (4/4)



#### Extended acknowledgements and study funding information

- AA-DHS NIH R01 DK071891 (Barry I. Freedman, PI); NIH R01 NS075107 (Barry I. Freedman, PI).
- ADVANCE ADVANCE genomic sub-studies were supported by grants from the Ministry of Science and Innovation from the Quebec Government, from Genome Quebec, from the Consortium Québécois du Médicament, from the Canadian Institutes of Health Research and from Medpharmgene, OPTITHERA Inc and Les Laboratoires Servier.
- AFTER EU The AFTER EU study is the Danish part of the EURAGEDIC study which was supported by the European Commission (contract QLG2-CT-2001–01669). The genotyping for this study was part of the Genetics of Diabetic Nephropathy (GenDN) study, primarily funded by Juvenile Diabetes Research Foundation (JDRF) International Prime Award Number 17-2013-8. Tarunveer S Ahluwalia was also funded by the GenDN study grant and Lundbeck foundation Travel Grant (Ref. Number 2013-14471).
  - AGES This study has been funded by NIA contract N01-AG-12100 and HHSN271201200022C with contributions from NEI, NIDCD and NHLBI, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). The study is approved by the Icelandic National Bioethics Committee, VSN: 00-063. The researchers thank the participants for their willingness to participate in the study.
  - We thank all participants in the Airwave Health Monitoring Study. The Airwave Airwave Health Monitoring Study is funded by the UK Home Office (780-TETRA) with additional support from the National Institute for Health Research (NIHR), and the Imperial College Biomedical Research Centre in collaboration with Imperial College NHS Healthcare Trust. The views expressed are those of the authors and not necessarily those of the sponsors. PE acknowledges support from the Medical Research Council and Public Health England (MR/L01341X/1) for the MRC-PHE Centre for Environment and Health; and the NIHR Health Protection Research Unit in Health Impact of Environmental Hazards (HPRU-2012-10141). This work used computing resources of the UK MEDical BIOinformatics partnership MED-BIO supported by the Medical Research (UK Council (MR/L01632X/1). PE is supported by the UK Dementia Research Institute which receives its funding from UK DRI Ltd funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. PE is associate director of the Health Data Research UK London funded by a consortium led by the UK Medical Research Council.
    - **Amish** We thank the Amish research volunteers for their long-standing partnership in research, and the research staff at the Amish Research Clinic for their work and dedication. The Amish contribution was supported by NIH grants R01 AG18728, R01 HL088119, U01 GM074518, U01 HL072515, U01 HL084756, and NIH K12RR023250, and P30 DK072488. Additional support was provided by the University of Maryland General Clinical Research Center, grant M01 RR 16500, the Baltimore Veterans Administration Medical Center Geriatrics Research, and the Paul Beeson Physician Faculty Scholars in Aging Program.
      - **ARIC** The Atherosclerosis Risk in Communities study has been funded in whole

or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I), R01HL087641, R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. The work of Anna Köttgen was supported by a Heisenberg Professorship (KO 3598/3-1) as well as CRCs 1140 and 992 of the German Research Foundation.

- ASPS, ASPS-Fam The authors thank the staff and the participants for their valuable contributions. We thank Birgit Reinhart for her long-term administrative commitment, Elfi Hofer for the technical assistance at creating the DNA bank, Ing. Johann Semmler and Anita Harb for DNA sequencing and DNA analyses by TaqMan assays and Irmgard Poelzl for supervising the quality management processes after ISO9001 at the biobanking and DNA analyses. The research reported in this article was funded by the Austrian Science Fond (FWF) grant number P20545-P05, P13180 and PI904 as well as by the Austrian National Bank (OeNB) Anniversary Fund grant number P15435 and the Austrain Federal Ministry of Science, Research and Economy under the aegis of the EU Joint Programme-Neurodegenerative Disease Research (JPND)-www.jpnd.eu. The Medical University of Graz supports the databank of the ASPS.
  - **BBJ** The BioBank Japan project is supported by the Ministry of Education, Culture, Sports, Sciences and Technology of Japanese government and the Japan Agency for Medical Research and Development.
  - **BES** BES was supported by the National Key Laboratory Fund, Beijing, China.
  - **BioMe** The Mount Sinai IPM Biobank Program is supported by The Andrea and Charles Bronfman Philanthropies. Ruth Loos is funded by R01DK110113, U01HG007417, R01DK101855, and R01DK107786.
  - **CHNS** The China Health and Nutrition Survey (CHNS) was supported by the China National Institute of Nutrition and Food Safety; the China Center for Disease Control; the National Institutes of Health (R01HD30880, R01HL108427, and R01DK104371); the Fogarty International Center of the National Institutes of Health; the China-Japan Friendship Hospital; the Chinese Ministry of Health; and the Carolina Population Center (R24 HD050924). Cassandra N. Spracklen was supported by the American Heart Association Postdoctoral Fellowship (17POST3650016).
  - **CHRIS** Full acknowledgements for the CHRIS study are reported at <u>http://translational-medicine.biomedcentral.com/articles/10.1186/s12967-015-0704-9#Declarations</u>. The CHRIS study was funded by the Department of Innovation, Research, and University of the Autonomous Province of Bolzano-South Tyrol.
    - CHS Cardiovascular Health Study: This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI

grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, and U01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

- **Cilento** We thank the populations of Cilento for their participation in the study. This work was supported by grants from the Italian Ministry of Universities and Research and CNR (Interomics Flagship Project, PON03PE\_00060\_7), the Assessorato Ricerca Regione Campania, the Fondazione con il SUD (2011-PDR-13), and the Istituto Banco di Napoli Fondazione to Marina Ciullo.
- **CoLaus** The CoLaus|PsyCoLaus study was and is supported by research grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (grants 3200B0–105993, 3200B0-118308, 33CSCO-122661, 33CS30-139468 and 33CS30-148401).
- **CROATIA-** 10001 Dalmatians: The Croatian Biobank (CROATIA) The CROATIA-Vis, Korcula, CROATIA-Korcula and CROATIA-Split were funded by grants from the CROATIA-Medical Research Council (UK), from the Republic of Croatia Ministry of Science, Education and Sports (108-1080315-0302; 216-1080315-0302) Split. and the Croatian Science Foundation (8875); and the CROATIA-Korčula **CROATIA-Vis** genotyping was funded by the European Union framework program 6 project EUROSPAN (LSHGCT2006018947). We thank the staff of several institutions in Croatia that supported the field work, including Zagreb Medical Schools, the Institute for Anthropological Research in Zagreb, the recruitment team from the Croatian Centre for Global Health, University of Split and all the study participants. We are grateful to the Helmholtz Zentrum Munchen (Munich, Germany), AROS Applied Biotechnology, (Aarhus, Denmark) and the Edinburgh Clinical Research facility, University of Edinburgh (Edinburgh, United Kingdom) for SNP array genotyping. Genetic analyses were supported by the MRC HGU "QTL in Health and Disease" core programme.
- **CZECH POST-** The study was supported by research grant 15-27109A provided by the Health Research Agency of the Ministry of Health, Czech Republic; Krka, tovarna zdravil, d.d., Novo mesto, Slovenia; Servier s.r.o., Czech Republic.
  - **DECODE** The study was funded by deCODE Genetics/Amgen inc. We thank the study subjects for their valuable participation and our colleagues, who contributed to data collection, sample handling, and genotyping.
    - **DESIR** The D.E.S.I.R. study has been funded by INSERM contracts with Caisse nationale de l'assurance Maladie des Travailleurs Salariés (CNAMTS), Lilly, Novartis Pharma, and Sanofi-Aventis; INSERM (Réseaux en Santé Publique, Interactions entre les déterminants de la santé, Cohortes Santé TGIR 2008); the Association Diabète Risque Vasculaire; the Fédération

Française de Cardiologie; La Fondation de France; Association de Langue Française pour l'Etude du Diabète et des Maladies Métaboliques (ALFEDIAM)/Société Francophone de Diabétologie (SFD); l'Office National Interprofessionnel des Vins (ONIVINS); Ardix Medical; Bayer Diagnostics; Becton Dickinson; Cardionics; Merck Santé; Novo Nordisk; Pierre Fabre; Roche; Topcon.

The D.E.S.I.R. Study Group. INSERM U1018: B. Balkau, P. Ducimetière, E. Eschwège; INSERM U367: F. Alhenc-Gelas; CHU D'Angers: Y Gallois, A. Girault; Centre de Recherche des Cordeliers, INSERM U1138, Bichat Hospital: F. Fumeron, M. Marre, R. Roussel; CHU de Rennes: F. Bonnet; CNRS UMR8090, Lille: A. Bonnefond, S. Cauchi, P. Froguel; Centres d'Examens de Santé: Alençon, Angers, Blois, Caen, Chateauroux, Chartres, Cholet, Le Mans, Orléans, Tours; Institut de Recherche Médecine Générale: J. Cogneau; General practitioners of the region; Institut inter-régional pour la Santé: C. Born, E. Caces, M. Cailleau, O Lantieri, J.G. Morea.

- **Diabetic Cohort** The Diabetic Cohort (DC) was supported by the individual research grant from the National Medical Research Council (NMRC) and the Biomedical Research Council (BMRC) of Singapore. The Genome Institute of Singapore provided services for genotyping.
- **DIACORE** Cohort recruiting and management was funded by the KfH Stiftung Präventivmedizin e.V. (Carsten A. Böger). Genome-wide genotyping was funded the Else Kröner-Fresenius-Stiftung (2012\_A147), the KfH Stiftung Präventivmedizin and the University Hospital Regensburg. Data analysis was funded by the Else Kröner-Fresenius Stiftung (2012\_A147).
  - **EGCUT** The EGCUT studies were financed by Estonian Government (grants IUT20-60 and IUT24-6) and by European Commission through the European Regional Development Fund in the frame of grant Estonian Center of Genomics/Roadmap II (project No. 2014-2020.4.01.16-0125) and grant GENTRANSMED (Project No. 2014-2020.4.01.15-0012) and through H2020 grant no 692145 (ePerMed).
    - **ERF** The Erasmus Rucphen Family (ERF) has received funding from the Centre for Medical Systems Biology (CMSB) and Netherlands Consortium for Systems Biology (NCSB), both within the framework of the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO). ERF study is also a part of EUROSPAN (European Special Populations Research Network) (FP6 STRP grant number 018947 (LSHG-CT-2006-01947)); European Network of Genomic and Genetic Epidemiology (ENGAGE) from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413; "Quality of Life and Management of the Living Resources" of 5th Framework Programme (no. QLG2-CT-2002-01254); FP7 project EUROHEADPAIN (nr 602633), the Internationale Stichting Alzheimer Onderzoek (ISAO); the Hersenstichting Nederland (HSN); and the JNPD under the project PERADES (grant number 733051021, Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease using multiple powerful cohorts, focused Epigenetics and Stem cell metabolomics). We thank all study participants and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, J. Vergeer for the supervision of the laboratory work, and P.

Snijders M.D. for his help in data collection of the data. Jun Liu, Cornelia M. van Duijn, and Ayse Demirkan have used exchange grants from the Personalized pREvention of Chronic DIseases consortium (PRECeDI). Ayse Demirkan is supported by a Veni grant (2015) from ZonMw.

- **ESTHER** The ESTHER study was funded by the Saarland state Ministry for Social Affairs, Health, Women and Family Affairs (Saarbrücken, Germany), the Baden-Württemberg state Ministry of Science, Research and Arts (Stuttgart, Germany), the Federal Ministry of Education and Research (Berlin, Germany) and the Federal Ministry of Family Affairs, Senior Citizens, Women and Youth (Berlin, Germany).
  - **FamHS** The study was supported by grant R01-DK-089256 from NIDDK and grant R01HL117078 from NHLBI.
    - **FHS** The Framingham Heart Study is supported by HHSN268201500001.
- **FINCAVAS** The Finnish Cardiovascular Study (FINCAVAS) has been financially supported by the Competitive Research Funding of the Tampere University Hospital (Grant 9M048 and 9N035), the Finnish Cultural Foundation, the Finnish Foundation for Cardiovascular Research, the Emil Aaltonen Foundation, Finland, the Tampere Tuberculosis Foundation, and EU Horizon 2020 (grant 755320 for TAXINOMISIS). The authors thank the staff of the Department of Clinical Physiology for collecting the exercise test data.
  - **Finrisk** We thank all individuals who participated in Finrisk surveys. Veikko Salomaa was supported by the Finnish Foundation for Cardiovascular Research. We thank the CSC IT center for science, Finland, for providing computational resources.
  - **GCKD** The GCKD study was funded by the German Ministry of Research and Education (Bundesminsterium für Bildung und Forschung, BMBF) and by the Foundation KfH Stiftung Präventivmedizin. Unregistered grants to support the study were provided by Bayer, Fresenius Medical Care and Amgen. Genotyping was supported by Bayer Pharma AG. Uromodulin measurements in GCKD were supported by the Swiss National Centre of Competence in Research Kidney Control of Homeostasis program and the Swiss National Science Foundation grant 31003A\_169850. The work of Matthias Wuttke was supported by DFG CRC 1140 and the Else Kroener Fresenius Forschungskolleg NAKSYS. The work of Yong Li was supported by DFG KO 3598/4-1. The work of Anselm Hoppmann was partly supported by NIDDK R01 DK087635-09.
- **Generation R** The Generation R Study is conducted by the Erasmus Medical Center in close collaboration with the School of Law and Faculty of Social Sciences of the Erasmus University Rotterdam, the Municipal Health Service Rotterdam area, Rotterdam, the Rotterdam Homecare Foundation, Rotterdam and the Stichting Trombosedienst & Artsenlaboratorium Rijnmond (STAR-MDC), Rotterdam. We acknowledge the contribution of children and parents, general practitioners, hospitals, midwives and pharmacies in Rotterdam. The generation and management of GWAS genotype data for the Generation R Study was done at the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Netherlands. We would like to thank Karol Estrada, Dr. Tobias A. Knoch, Anis Abuseiris, Luc V. de Zeeuw, and Rob de Graaf, for their help in

creating GRIMP, BigGRID, MediGRID, and Services@MediGRID/D-Grid, [funded by the German Bundesministerium fuer Forschung und Technology; grants 01 AK 803 A-H, 01 IG 07015 G] for access to their grid computing resources. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Manoushka Ganesh, Lizbeth Herrera and Marjolein Peters for their help in creating, managing and QC of the GWAS database. The general design of Generation R Study is made possible by financial support from the Erasmus MC, University Medical Center, Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw) and the Ministry of Health, Welfare and Sport. Janine Felix and Vincent Jaddoe received additional funding from the European Union's Horizon 2020 research and innovation programme (733206, LIFECYCLE). Fernando Rivadeneira received additional funding from the Netherlands Organization for Health Research and Development (VIDI 016. 136. 367). This project received additional funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 633595 (DynaHEALTH). Vincent Jaddoe received additional funding from the Netherlands Organization for Health Research and Development (VIDI 016.136.361), European Research Council (ERC Consolidator Grant, ERC-2014-CoG-648916) and European Union's FP-7 programme (Early Nutrition).

- GS:SFHS Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. We thank all the families who took part, the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award "STratifying Resilience and Depression Longitudinally" (STRADL) Reference 104036/Z/14/Z).
  - **GSK** Funding Source: Max-Planck Society, German Federal Ministry of Education and Research (BMBF) in the framework of the National Genome Research Network (NGFN), Foerderkennzeichen 01GS0481.
- HANDLS The authors thank all study participants and the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study medical staff for their contributions. The HANDLS study was supported by the Intramural Research Program of the NIH, National Institute on Aging and the National Center on Minority Health and Health Disparities (project # Z01-AG000513 and human subjects protocol number 09-AG-N248). Data analyses for the HANDLS study utilized the high-performance computational resources of the Biowulf Linux cluster at the National Institutes of Health. Bethesda. MD. (http://biowulf.nih.gov; http://hpc.nih.gov).
- **HYPERGENES** Funding Source: HYPERGENES project (FP7-HEALTH-F4-2007-201550) and InterOmics (PB05 MIUR-CNR Italian Flagship Project).

- **INGI-CARL** The project was approved by the local administration of Carlantino, the Health Service of Foggia Province, Italy, and ethical committee of the IRCCS Burlo-Garofolo of Trieste. We thank the people of Carlantino for their support.
  - **INGI-FVG** Project co-financed by the European Regional Development Fund under the Regional Operational Programme of Friuli Venezia Giulia - Objective "Regional Competitiveness and Employment" 2007/2013, Telethon Foundation (GGP09037), Fondo Trieste (2008), Regione FVG (L.26.2008), and Italian Ministry of Health (RC16/06, ART. 13 D.LGS 297/99) (to Paolo Gasparini). We thank the people of Friuli Venezia Giulia Region for their support.
  - **INGI-VBI** The research was supported by funds from Compagnia di San Paolo, Torino, Italy; Fondazione Cariplo, Italy and Ministry of Health, Ricerca Finalizzata 2011 and CCM 2010 to Daniela Toniolo. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank the inhabitants of the VB that made this study possible, the local administrations, the Tortona and Genova archdiocese and the ASL-22, Novi Ligure (AI) for support. We thank Clara Camaschella for data collection supervision and organization of the clinical data collection, Fiammetta Viganò for technical help, and Corrado Masciullo for the analysis platform.
- INTERVAL We thank all INTERVAL voluntary participants. We thank the INTERVAL study co-ordination teams (at the Universities of Cambridge and Oxford and at NHS Blood and Transplant [NHSBT]), including the blood donation staff at the 25 static centers, for their help with INTERVAL participant recruitment and study fieldwork, as well as the Cambridge BioResource and NHSBT staff for their help with volunteer recruitment. We thank members of the Cambridge BioResource Scientific Advisory Board and Management Committee for their support of our study and the NIH Research Cambridge Biomedical Research Centre for funding (RG64219). The INTERVAL academic coordinating centre receives core support from the UK Medical Research Council (G0800270), the BHF (SP/09/002), the NIHR, and Cambridge Biomedical Research Centre, as well as grants from the European Research Council (268834), the European Commission Framework Programme 7 (HEALTH-F2-2012-279233), MSD, and Pfizer. The INTERVAL study is funded by NHSBT (11-01-GEN) and has been supported by the NIHR-BTRU in Donor Health and Genomics (NIHR BTRU-2014-10024) at the University of Cambridge in partnership with NHSBT. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health of England, or NHSBT. The Cardiovascular Epidemiology Unit at the University of Cambridge is funded by UK MRC (G0800270), BHF (SP/09/002), UK NIHR Cambridge Biomedical Research Centre, ERC (268834), and European Commission Framework Programme 7 (HEALTH-F2-2012-279233). Willem H. Ouwehand is a NIHR Senior Investigator. David J. Roberts was supported by the NIHR Programme "Erythropoiesis in Health and Disease" (NIHR-RP-PG-0310-1004). John Danesh is a BHF Professor, European Research Council Senior Investigator, and NIHR Senior Investigator. Nicole Soranzo is supported by the Wellcome Trust (WT098051 and WT091310), the EU FP7 (EPIGENESYS 257082 and BLUEPRINT

HEALTH-F5-2011-282510).

- JHS The Jackson Heart Study (JHS) is supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi State Department of Health (HHSN268201800015I/HHSN26800001) and the Mississippi Medical Center (HHSN268201800010I. Universitv of HHSN268201800011I and HHSN268201800012I) contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute for Minority Health and Health Disparities (NIMHD). The authors also wish to thank the staffs and participants of the JHS. James G. Wilson is supported by U54GM115428 from the National Institute of General Medical Sciences. Laura M. Raffield is supported by T32 HL129982.
- **JUPITER** The JUPITER trial and its genetic substudy were funded by AstraZeneca.
  - **KORA** The KORA research platform (KORA, Cooperative Health Research in the Region of Augsburg) was initiated and financed by the Helmholtz Zentrum München German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ. Statistical KORA analyses were supported by DFG BO-3815/4-1 (to Carsten A. Böger) and BMBF 01ER1206 and 01ER1507 (to Iris M. Heid) and by University of Regensburg.

LIFE-Adult, LIFE-Adult, LIFE-Heart, and LIFE-Child, are funded by the Leipzig LIFE-Heart, LIFE-Child LIFE-Child LIFE-Child, are funded by the Leipzig unit affiliated to the Medical Faculty of the University of Leipzig. LIFE is funded by means of the European Union, by the European Regional Development Fund (ERDF) and by funds of the Free State of Saxony within the framework of the excellence initiative.

- The Lifelines Cohort Study, and generation and management of GWAS Lifelines genotype data for the Lifelines Cohort Study is supported by the Organization of Scientific Research Netherlands NWO (grant 175.010.2007.006), the Economic Structure Enhancing Fund (FES) of the Dutch government, the Ministry of Economic Affairs, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the Northern Netherlands Collaboration of Provinces (SNN), the Province of Groningen, University Medical Center Groningen, the University of Groningen, Dutch Kidney Foundation and Dutch Diabetes Research Foundation. The authors wish to acknowledge the services of the Lifelines Cohort Study, the contributing research centers delivering data to Lifelines, and all the study participants.
- Livingbiobank The genotyping was funded by the Agency for Science, Technology and Research, Singapore (https://www.a-star.edu.sg/), and by Merck Sharp & Dohme Corp., Whitehouse Station, NJ USA (http://www.merck.com). The participants were from the MEC study (funded by the Biomedical Research Council (BMRC 03/1/27/18/216), National Medical Research Council (0838/2004), National Research Foundation (through BMRC 05/1/21/19/425 and 11/1/21/19/678), Ministry of Health, Singapore, National University of Singapore and National University Health System,

Singapore), and The SH2012 study (funded by the Ministry of Health, Singapore, National University of Singapore and National University Health System, Singapore).

- **LLFS** The study was supported by grants: U01AG023746, U01AG023712, U01AG023749, U01AG023755, and U01AG023744 from NIA.
- LOLIPOP The LOLIPOP study is supported by the National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre Imperial College Healthcare NHS Trust, the British Heart Foundation (SP/04/002), the Medical Research Council (G0601966, G0700931), the Wellcome Trust (084723/Z/08/Z, 090532 & 098381) the NIHR (RP-PG-0407-10371), the NIHR Official Development Assistance (ODA, award 16/136/68), the European Union FP7 (EpiMigrant, 279143), and H2020 programs (iHealth-T2D, 643774). We acknowledge support of the MRC-PHE Centre for Environment and Health, and the NIHR Health Protection Research Unit on Health Impact of Environmental Hazards. The work was carried out in part at the NIHR/Wellcome Trust Imperial Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the Imperial College Healthcare NHS Trust, the NHS, the NIHR or the Department of Health. We thank the participants and research staff who made the study possible. JC is supported by the Singapore Ministry of Health's National Medical Research Council under its Singapore Investigator (STaR) Award Translational Research (NMRC/STaR/0028/2017).
  - **LURIC** LURIC was supported by the 7th Framework Program of the EU (AtheroRemo, grant agreement number 201668 and RiskyCAD, grant agreement number 305739). The work of W.M. and M.E.K. is supported as part of the Competence Cluster of Nutrition and Cardiovascular Health (nutriCARD) which is funded by the German Ministry of Education and Research (grant agreement no. 01EA1411A). The authors thank the LURIC study team involved in patient recruitment as well as sample and data handling, and the laboratory staff at the Ludwigshafen General Hospital and the universities of Freiburg, Ulm and Heidelberg, Germany.
- **MDC-CC** This study was supported by the European Research Council (Consolidator grant nr 649021, Orho-Melander), the Swedish Research Council, the Swedish Heart and Lung Foundation, the Novo Nordic Foundation, the Swedish Diabetes Foundation, and the Påhlsson Foundation, and by equipment grants from the Knut and Alice Wallenberg Foundation, the Region Skåne, Skåne University Hospital, the Linneus Foundation for the Lund University Diabetes Center and Swedish Foundation for Strategic Research for IRC15-0067.
  - MESA MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-00040, UL1-TR-001079, UL1-TR-001420, UL1-TR-001881, and DK063491. MESA Family is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support is

provided by grants and contracts R01HL071051, R01HL071205, R01HL071250, R01HL071251, R01HL071258, R01HL071259, by the National Center for Research Resources, Grant UL1RR033176, and the National Center for Advancing Translational Sciences, Grant UL1TR001881. This publication was developed under a STAR research assistance agreement, No. RD831697 (MESA Air), awarded by the U.S. Environmental protection Agency. It has not been formally reviewed by the EPA. The views expressed in this document are solely those of the authors and the EPA does not endorse any products or commercial services mentioned in this publication.

- **METSIM** Michael Boehnke was supported by NIH grant DK062370.
- **MICROS** We thank all study participants, all primary care practitioners, and the personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their participation and collaboration in the research project. The study was supported by the Ministry of Health and Department of Educational Assistance, University and Research of the Autonomous Province of Bolzano, the South Tyrolean Sparkasse Foundation, and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947).
  - **MVP** This work was supported by the MVP-VA Award #I01BX003360 (PI Adriana M. Hung).
- **MyCode** (Geisinger) We would like to acknowledge the participants, staff, and our colleagues associated with the Geisinger MyCode Community Health Initiative. We also thank the staff of the PACDC of Geisinger for assistance with the phenotypic data, and the staff of the Biomedical & Translational Informatics and Kidney Health Research Institute.
  - **NEO** The authors of the NEO study thank all individuals who participated in the Netherlands Epidemiology in Obesity study, all participating general practitioners for inviting eligible participants and all research nurses for collection of the data. We thank the NEO study group, Pat van Beelen, Petra Noordijk and Ingeborg de Jonge for the coordination, lab and data management of the NEO study. The genotyping in the NEO study was supported by the Centre National de Génotypage (Paris, France), headed by Jean-Francois Deleuze. The NEO study is supported by the participating Departments, the Division and the Board of Directors of the Leiden University Medical Center, and by the Leiden University, Research Profile Area Vascular and Regenerative Medicine. Dennis Mook-Kanamori is supported by Dutch Science Organization (ZonMW-VENI Grant 916.14.023).
  - The infrastructure for the NESDA study (www.nesda.nl) is funded through NESDA the Geestkracht program of the Netherlands Organisation for Health Research and Development (ZonMw, grant no. 10-000-1002) and financial contributions by participating universities and mental health care organizations (VU University Medical Center, GGZ inGeest, Leiden University Medical Center, Leiden University, GGZ Rivierduinen, University Medical Center Groningen, University of Groningen, Lentis, GGZ Friesland, GGZ Drenthe, and Rob Giel Onderzoekscentrum). Statistical analyses were carried out on the Genetic Cluster Computer

(<u>http://www.geneticcluster.org</u>), which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the Dutch Brain Foundation.

- **OGP** The Ogliastra Genetic Park study was supported by grant from the Italian Ministry of Education, University and Research (MIUR) no. 5571/DSPAR/2002. We thank all study participants for their contributions and the municipal administrations for their economic and logistic support.
- **ORCADES** The Orkney Complex Disease Study (ORCADES) was supported by the Chief Scientist Office of the Scottish Government (CZB/4/276, CZB/4/710), a Royal Society URF to James F. Wilson, the MRC Human Genetics Unit quinquennial programme "QTL in Health and Disease", Arthritis Research UK and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947). DNA extractions were performed at the Wellcome Trust Clinical Research Facility in Edinburgh. We would like to acknowledge the invaluable contributions of the research nurses in Orkney, the administrative team in Edinburgh, the people of Orkney, and the data analysts in particular Dr Thibaud Boutin for the genotype imputation to the HRC reference panel.
  - **PIVUS** The ULSAM study was supported by Wellcome Trust grants WT098017, WT064890, WT090532, Uppsala University, Uppsala University Hospital, the Swedish Research Council and the Swedish Heart-Lung Foundation. Cecilia M. Lindgren is supported by the Li Ka Shing Foundation, WT-SSI/John Fell funds and by the NIHR Biomedical Research Centre, Oxford, by Widenlife and NIH (5P50HD028138-27). Johan Ärnlöv was supported by The Swedish Research Council, Swedish Heart-Lung Foundation, Dalarna University and Uppsala University
- **PREVEND** The Prevention of Renal and Vascular Endstage Disease Study (PREVEND) genetics is supported by the Dutch Kidney Foundation (Grant E033), the EU project grant GENECURE (FP-6 LSHM CT 2006 037697), the National Institutes of Health (grant LM010098), the Netherlands organization for health research and development (NWO VENI grant 916.761.70), and the Dutch Inter University Cardiology Institute Netherlands (ICIN). Niek Verweij was supported by NWO VENI grant 016.186.125.
- **POPGEN** The PopGen 2.0 network was supported by a grant from the German Ministry for Education and Research (01EY1103). Sandra Freitag-Wolf was supported by German Research Foundation, Clusters of Excellence 306, Inflammation at Interfaces.
- QIMR We acknowledge funding by Australian National Health and Medical adolescent Research Council (NHMRC) grants 241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 552485, 552498 and Australian Research Council grants A7960034, A79906588, A79801419, DP0770096, DP0212016, DP0343921 for building and maintaining the adolescent twin family resource through which samples were collected.
- **QIMR adult** We acknowledge the contributions of many staff in the Genetic Epidemiology Unit, Queensland Institute of Medical Research, in interviewing study participants, sample processing and DNA extraction, and data management. Funding for aspects of this work was provided by the Australian National Health and Medical Research Council (241944,

339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 552485, 552498), the Australian Research Council (A7960034, A79906588, A79801419, DP0770096, DP0212016, DP0343921), the EU 5th Framework Programme GenomEUtwin Project (QLG2-CT-2002-01254), and the U.S. National Institutes of Health (AA07535, AA10248, AA11998, AA13320, AA13321, AA13326, AA14041, AA17688, DA12854, MH66206 ). G.W.M. was supported by National Health and Medical Research Council (NHMRC) Fellowship Schemes.

- The Rotterdam Study (RS) has been approved by the Medical Ethics RS Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG). The RS has been entered into the Netherlands National Trial Register (NTR; www.trialregister.nl) and into the WHO International Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp/network/primary/en/) under shared catalogue number NTR6831. All participants provided written informed consent to participate in the study and to have their information obtained from treating physicians. The generation and management of GWAS genotype data for the RS (RS I, RS II, RS III) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine. Erasmus MC. Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, MSc, and Carolina Medina-Gomez, MSc, for their help in creating the GWAS database, and Karol Estrada, PhD, Yurii Aulchenko, PhD, and Carolina Medina-Gomez, MSc, for the creation and analysis of imputed data. The RS is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the RS and the participating general practitioners and pharmacists.
- **SCES** The Singapore Chinese Eye Study (SCES) was supported by grants from the National Medical Research Council (STaR/0003/2008), the Singapore Bio Imaging Consortium (C-011/2006) and the Biomedical Research Council (08/1/35/19/550). The Genome Institute of Singapore provided services for genotyping.
- SHIP/SHIP Trend
  SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network 'Greifswald

Approach to Individualized Medicine (GANI\_MED)' funded by the Federal Ministry of Education and Research (grant 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg- West Pomerania. The University of Greifswald is a member of the Caché Campus program of the InterSystems GmbH.

- **SiMES** The Singapore Malay Eye Study (SiMES) was funded by the National Medical Research Council (NMRC 0796/2003 and NMRC/STaR/0003/2008) and Biomedical Research Council (BMRC, 09/1/35/19/616). The Genome Institute of Singapore provided services for genotyping.
- **SINDI** The Singapore Indian Eye Study (SINDI) was funded by grants from the Biomedical Research Council of Singapore (BMRC 09/1/35/19/616 and 08/1/35/19/550), and the National Medical Research Council of Singapore (NMRC/STaR/0003/2008). The Genome Institute of Singapore provided services for genotyping.
- SCHS CHD cases and controls The Singapore Chinese Health Study was supported by the National Institutes of Health, USA (RO1 CA144034 and UM1 CA182876), the nested case-control study of myocardial infarction by the Singapore National Medical Research Council (NMRC 1270/2010), and genotyping by the HUJ-CREATE Programme of the National Research Foundation, Singapore (Project Number 370062002).
  - **SKIPOGH** The SKIPOGH study was supported by a Swiss national science foundation grant (FN33CM30-124087 and FN33CM30-140331), by the Swiss National Centres of Competence in Research Kidney and TransCure.
- **SOLID-TIMI 52** The SOLID-TIMI 52 trial was supported and funded by grants from GlaxoSmithKline.
  - **Sorbs** This work was supported by grants from the German Research Foundation (SFB-1052 "Obesity mechanisms" A01, B03, SPP 1629 TO 718/2- 1), from the German Diabetes Association, from the DHFD (Diabetes Hilfs- und Forschungsfonds Deutschland) and from IFB Adiposity Diseases (AD2-060E, AD2-06E95, AD2-06E99). IFB Adiposity Diseases is supported by the Federal Ministry of Education and Research (BMBF), Germany, FKZ: 01EO1501.
    - **SP2** The Singapore Prospective Study Program (SP2) were supported by the individual research grant and clinician scientist award schemes from the National Medical Research Council (NMRC) and the Biomedical Research Council (BMRC) of Singapore. The Genome Institute of Singapore provided services for genotyping.
  - **STABILITY** The STABILITY trial was supported and funded by grants from GlaxoSmithKline.
    - **TRAILS** TRAILS (TRacking Adolescents' Individual Lives Survey) is a collaborative project involving various departments of the University Medical Center and University of Groningen, the University of Utrecht, the Radboud Medical Center Nijmegen, and the Parnassia Bavo group, all in the Netherlands. TRAILS has been financially supported by grants from the Netherlands

Organization for Scientific Research NWO (Medical Research Council program grant GB-MW 940-38-011; ZonMW Brainpower grant 100-001-004; ZonMw Risk Behavior and Dependence grant 60-60600-97-118; ZonMw Culture and Health grant 261-98-710; Social Sciences Council medium-sized investment grants GB-MaGW 480-01-006 and GB-MaGW 480-07-001; Social Sciences Council project grants GB-MaGW 452-04-314 and GB-MaGW 452-06-004; NWO large-sized investment grant 175.010.2003.005; NWO Longitudinal Survey and Panel Funding 481-08-013 and 481-11-001); the Dutch Ministry of Justice (WODC), the European Science Foundation (EuroSTRESS project FP-006), Biobanking and Biomolecular Resources Research Infrastructure BBMRI-NL (CP 32), the participating universities, and Accare Center for Child and Adolescent Psychiatry. Statistical analyses were carried out on the Genetic Cluster Computer (http://www.geneticcluster.org), which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the Dutch Brain Foundation. We are grateful to all adolescents who participated in this research and to everyone who worked on this project and made it possible.

- TwinGene TwinGene is a sub-study of the Swedish Twin Registry which is managed by Karolinska Institutet and receives funding through the Swedish Research Council under the grant no 2017-00641. TwinGene was supported by grants from the Swedish Research Council (M-2005-1112), GenomEUtwin (EU/QLRT-2001-01254; QLG2-CT-2002-01254), NIH DK U01-066134, The Swedish Foundation for Strategic Research (SSF). Heart and Lung foundation no. 20070481. Analysis on renal biomarkers was supported by grants from Stockholm County Council, The Swedish Society of Medicine (SLS-412071), the Serafimer Hospital Foundation and Stiftelsen för Njursjuka.
  - **ULSAM** The ULSAM study was supported by Wellcome Trust grants WT098017, WT064890, WT090532, Uppsala University, Uppsala University Hospital, the Swedish Research Council and the Swedish Heart-Lung Foundation. Johan Ärnlöv was supported by The Swedish Research Council, Swedish Heart-Lung Foundation, Dalarna University and Uppsala University.
- Vanderbilt The data used for the analyses were obtained from Vanderbilt University Medical Center's BioVU, which is supported by numerous sources: institutional funding, private agencies, and federal grants. These include the NIH funded Shared Instrumentation Grant S10RR025141; and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Genomic data are also supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional funding sources listed at https://victr.vanderbilt.edu/pub/biovu/. Jacklyn N. Hellwege is supported by the Vanderbilt Molecular and Genetic Epidemiology of Cancer training program, funded by T32CA160056.
  - VIKING The Viking Health Study Shetland (VIKING) was supported by the MRC Human Genetics Unit quinquennial programme grant "QTL in Health and Disease". DNA extractions and genotyping were performed at the Edinburgh Clinical Research Facility, University of Edinburgh. We acknowledge the contributions of the research nurses in Shetland, the administrative team in Edinburgh, the people of Shetland, and the data

analysts, in particular Dr Thibaud Boutin for the genotype imputation to the HRC reference panel.

- **WGHS** The Women's Genome Health Study (WGHS) is supported by the National Heart, Lung, and Blood Institute (HL043851 and HL080467) and the National Cancer Institute (CA047988 and UM1CA182913) with funding for genotyping provided by Amgen.
  - YFS The Young Finns Study has been financially supported by the Academy of Finland: grants 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio. Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research ; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; and EU Horizon 2020 (grant 755320 for TAXINOMISIS); and European Research Council (grant 742927 for MULTIEPIGEN project); Tampere University Hospital Supporting Foundation. We thank the teams that collected data at all measurement time points; the persons who participated as both children and adults in these longitudinal studies; and biostatisticians Irina Lisinen, Johanna Ikonen, Noora Kartiosuo, Ville Aalto, and Jarno Kankaanranta for data management and statistical advice.

#### LifeLines Cohort Study – Author Group

Behrooz Z Alizadeh (1), H Marike Boezen (1), Lude Franke (2), Pim van der Harst (3), Gerjan Navis (4), Marianne Rots (5), Morris Swertz (2), Bruce HR Wolffenbuttel (6), Cisca Wijmenga (2)

- (1) Department of Epidemiology, University of Groningen, University Medical Center Groningen, The Netherlands
- (2) Department of Genetics, University of Groningen, University Medical Center Groningen, The Netherlands
- (3) Department of Cardiology, University of Groningen, University Medical Center Groningen, The Netherlands
- (4) Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, The Netherlands
- (5) Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, The Netherlands
- (6) Department of Endocrinology, University of Groningen, University Medical Center Groningen, The Netherlands